---
document_datetime: 2025-04-15 12:07:52
document_pages: 16
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: clopidogrel-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 9.9462769
conversion_datetime: 2025-12-24 18:47:04.960349
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Clopidogrel Viatris

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0049/G            | This was an application for a group of variations. B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging container without a complete deletion of a strength | 16/05/2024                          |                                             | SmPC, Labelling and PL           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | pharmaceutical form - Changes in the composition of the finished product - Other excipients Change that is supported by a bioequivalence study                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             | or B.II.a.3.b.5 (excipients) -   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------|
| IB/0050/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO data is required to be submitted by | 07/12/2023 | 18/12/2023 | SmPC and PL | new additional the MAH           |
| IB/0047/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.z - Quality change - Active substance - Other                                                                                                                                       | 01/06/2023 | n/a        |             | variation                        |

<div style=\"page-break-after: always\"></div>

| IB/0048/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 26/05/2023   | n/a        |             |                       |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-----------------------|
| IB/0046     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                 | 03/08/2022   | 04/08/2023 | SmPC and PL |                       |
| IB/0045/G   | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.III.2.a.1 - Change of specification(s) of a former substance to fully comply | 02/06/2022   | n/a        |             | non EU Pharmacopoeial |

<div style=\"page-break-after: always\"></div>

|             | with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF                                                                         |            |            |                                  |               |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------|
| N/0044      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                              | 14/03/2022 | 04/08/2023 | PL                               |               |
| IB/0043     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH  | 17/01/2022 | 03/02/2022 | SmPC, Labelling and PL           |               |
| T/0042      | Transfer of Marketing Authorisation                                                                                                                                                                                                                           | 19/10/2021 | 09/11/2021 | SmPC, Labelling and PL           |               |
| IAIN/0041   | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                                                                                               | 06/10/2021 | 25/10/2021 | SmPC, Labelling and PL           |               |
| IAIN/0040/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a | 28/07/2021 | 25/10/2021 | SmPC, Annex II, Labelling and PL | manufacturing |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes   |            |            |                        | site   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------|
| IB/0039   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                               | 17/05/2021 | 01/06/2021 | SmPC, Annex II and PL  |        |
| T/0037    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 28/01/2021 | 12/02/2021 | SmPC, Labelling and PL |        |
| IAIN/0038 | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                                                                                                                                                                                                                                                                                                                                            | 13/01/2021 | 11/02/2021 | SmPC, Labelling and PL |        |
| IB/0036   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by                                                                                                                                                                                                                                                       | 04/11/2020 | 11/02/2021 | SmPC and PL            |        |

<div style=\"page-break-after: always\"></div>

|           | the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |             |         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------|
| IB/0035/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 30/01/2020 | 04/05/2020 | SmPC and PL | the MAH |
| IAIN/0034 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 27/09/2019 | 04/05/2020 | SmPC and PL |         |
| IB/0033/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO                                                    | 23/05/2019 | 04/05/2020 | SmPC and PL |         |

<div style=\"page-break-after: always\"></div>

|           | additional data is required to be submitted by MAH                                                                                                                                                                                                           |            |            |                        | new the           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------|
| IB/0032   | B.II.b.4.e - Change in the batch size (including batch size ranges) of the finished product - More than 10- fold increase compared to the originally approved batch size for immediate release (oral) pharmaceutical form                                    | 14/05/2019 | n/a        |                        |                   |
| N/0031    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 18/09/2018 | 17/04/2019 | PL                     |                   |
| IAIN/0030 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                   | 01/06/2018 | 17/04/2019 | SmPC, Labelling and PL |                   |
| IB/0029   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 23/04/2018 | 17/04/2019 | SmPC and PL            |                   |
| IB/0028   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                         | 24/07/2017 | n/a        |                        |                   |
| IB/0027/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following same change for the reference                                                                              | 18/05/2017 | 31/05/2017 | SmPC, Labelling and PL | assessment of the |

<div style=\"page-break-after: always\"></div>

|        | of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                           |            |            |             | product - Implementation   |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------|
| N/0026 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 29/03/2016 | 04/07/2016 | PL          |                            |
|        | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following | 22/01/2016 | 04/07/2016 | SmPC and PL | IB/0025/G                  |

<div style=\"page-break-after: always\"></div>

|         | the MAH                                                                                                                                                                                                                                                      |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0020 | B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF                                                                                           | 24/09/2015 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0023 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 08/07/2015 | 04/07/2016 | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| R/0017  | Renewal of the marketing authorisation.                                                                                                                                                                                                                      | 24/07/2014 | 18/09/2014 | SmPC, Labelling and PL | The MAH has not performed any efficacy studies in the period after the initial marketing authorisation or provided any literature review on the efficacy/effectiveness. The MAH refers in the clinical overview to the modifications of the SmPC confirming the efficacy of clopidogrel in the proposed indications. On the basis of the review of the safety information covering the period of this renewal, the CHMP concluded that the safety profile of Apotex remains favourable in the approved indications. In line with the reference medicinal product it is recommended to continue close monitoring of all reports of adverse reactions received from worldwide sources and the occurrence of late stent thrombosis after clopidogrel withdrawal for the next reporting interval and cumulatively follow the literature for potential new emerging information that may alter the efficacy-safety of clopidogrel. The CHMP recommends that the renewal be granted with |

<div style=\"page-break-after: always\"></div>

|                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |             | unlimited validity.               |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/820/2 01311 | Periodic Safety Update EU Single assessment - acetylsalicylic acid / clopidogrel, clopidogrel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 10/07/2014 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0019/G         | This was an application for a group of variations. To update sections 4.4 and 4.5 of the SmPC to add information on an interaction with the selective serotonin reuptake inhibitors (SSRIs) in section 4.5 and consequential information concerning this interaction in section 4.4. The Package leaflet has been updated accordingly. To update 4.8 of the SmPC to add \"Rash exfoliative\" as a new undesirable effect. Furthermore minor editorial correction to DE, HR, NO and PL text were introduced. These changes have been previously approved for the reference medicinal product Plavix in WS/476 and WS/477 respectively. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO | 29/04/2014 | 18/09/2014 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

|             | the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                 |         |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------|
| IB/0016     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                         | 03/01/2014 | 18/09/2014 | SmPC and PL     |         |
| IB/0015/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 31/10/2013 | 18/09/2014 | SmPC and PL     | the MAH |
| IAIN/0014/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging                                                                                                                                                                                                                                                                                                                  | 14/10/2013 | 18/09/2014 | Annex II and PL | site    |

<div style=\"page-break-after: always\"></div>

|           | Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                           |            |            |                                  | B.II.b.1.b -   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------|
| IB/0013/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 11/10/2013 | 18/09/2014 | SmPC, Annex II, Labelling and PL | the MAH        |
| II/0012   | To add an alternative manufacturer of the active substance, clopidogrel besilate. B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is supported by an ASMF                                                                                                                                                                                                                                                                                                     | 25/04/2013 | n/a        |                                  |                |

<div style=\"page-break-after: always\"></div>

| N/0010    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 04/03/2013   | 18/09/2014   | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0011 | To replace the Detailed Description of the Pharmacovigilance System (DDPS) with the Pharmacovigilance System Master File (PSMF). C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                  | 18/02/2013   | n/a          |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0009/G | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                            | 27/03/2012   | 15/10/2012   | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0008/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 02/08/2011   | n/a          | SmPC and PL            | Update of sections 4.2 \"Posology and method of administration\" and 5.1 \"Phamacodynamic properties\" of clopidogrel SPC to include new paediatric information available for clopidogrel. Update of section 4.1 with addition of indication \"Prevention of atherothrombotic events\". Editorial changes to harmonise the text with the Plavix text as well as a change to the local representatives telephone number in the package leaflet. |

<div style=\"page-break-after: always\"></div>

| IB/0007/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 17/05/2011   | n/a   | SmPC, Annex   | To update the Product Information as already approved for                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH |              |       | II and PL     | the reference product Plavix. - Additional indication (Acute Coronary Syndrome) - Extension of Indication: Extension of the acute coronary syndrome (ACS) indication as follows: \"ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy\". - Update of Summary of Product Characteristics and Package Leaflet to reword the indication as follows: \"Non- ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).\" This grouped variation also includes the following change that was already approved for the reference product Plavix: - Amendments were introduced in the Summary of Product Characteristics (SPC) and Package Leaflet to update sections 4.2 \"Posology and method of administration\", 4.4 \"Special warnings and precautions for use\", 4.5 \"Interaction with other medicinal products and other forms of interaction\" and 5.2 \"Pharmacokinetic properties\" of clopidogrel/acetylsalicylic acid (ASA) SPC to include new information on the variability of response to clopidogrel due to either genetic variations of the CYP2C19 enzyme or concomitant use of drugs that inhibit the CYP2C19 enzyme such as proton pump inhibitor (PPI). In addition, section 4.8 has been amended with minor details on the CURE study. Additional changes have been added to the SPC and Package Leaflet in order to bring it in line with the revised QRD template (version 7.3) |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                  |            |            |                 | Furthermore, the DDPS version number and date were deleted as a change to Annex lIB as stated in the procedural announcement of October and November 2010.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0005   | To add an alternative route of synthesis of the active substance (clopidogrel besylate) at the already approved manufacturing site. B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions | 18/11/2010 | 25/11/2010 |                 |                                                                                                                                                              |
| IB/0006   | C.I.8.b - Introduction of a new Pharmacovigilance system - which has been assessed by the relevant NCA/EMA for another product of the same MAH                                                                                                                                                                                                   | 28/10/2010 | n/a        | Annex II        | To update the Pharmacovigilance system to version 7.0 of the MAH, Apotex Europe B.V.                                                                         |
| IB/0004   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                   | 28/07/2010 | n/a        | SmPC and PL     |                                                                                                                                                              |
| IB/0003/G | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.1.a - Replacement or addition of a           | 21/05/2010 | n/a        | Annex II and PL |                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         | site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.b.2 - Change to batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size A.7 - Administrative change - Deletion of manufacturing sites   |            |            |                        |                                                                                           |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------|
| IB/0002 | IB_02_Change in the name of the medicinal product                                                                                                                                                                                                                                                                                                                                                                                                           | 20/01/2010 | n/a        | SmPC, Labelling and PL |                                                                                           |
| T/0001  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                         | 25/11/2009 | 11/12/2009 | SmPC, Labelling and PL | The Marketing Authorisation Holder was transferred from Mylan S.A.S. to Apotex Europe BV. |